Publications by authors named "Jaafar Bennouna"

Background: Patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapies. Nivolumab plus ipilimumab has shown clinical benefit in nonrandomized studies of MSI-H or dMMR metastatic colorectal cancer.

Methods: In this phase 3 open-label trial, we randomly assigned patients with unresectable or metastatic colorectal cancer and MSI-H or dMMR status according to local testing to receive, in a 2:2:1 ratio, nivolumab plus ipilimumab, nivolumab alone, or chemotherapy with or without targeted therapies.

View Article and Find Full Text PDF

Introduction: Chemotherapy combined with immunotherapy (CT-IO) is the standard treatment for patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). This study evaluates the effectiveness of second-line (2L) following CT-IO.

Patients And Methods: All patients from 10 centers who received a 2L after a first-line CT-IO were included.

View Article and Find Full Text PDF
Article Synopsis
  • Treatment options for advanced esophageal squamous cell carcinoma (ESCC) are improving, with current guidelines advocating for the use of pembrolizumab plus chemotherapy as a first-line treatment.
  • Combining antiangiogenic therapies like lenvatinib with immune checkpoint inhibitors (such as pembrolizumab) can enhance immune responses against tumors by shifting the tumor environment to be more immune-supportive.
  • The LEAP-014 study is a phase III clinical trial designed to evaluate the effectiveness of lenvatinib with pembrolizumab and chemotherapy in improving overall and progression-free survival in patients with advanced ESCC.
View Article and Find Full Text PDF

Background: Lung cancers represent the main cause of cancer related-death worldwide. Recently, immunotherapy alone or in combination with chemotherapy has deeply impacted the therapeutic care leading to an improved overall survival. However, relapse will finally occur, with no efficient second line treatment so far.

View Article and Find Full Text PDF

Introduction: The number of Advanced Practice Nurses (APNs) has significantly increased in France since 2019, with the number of graduates expected to reach 1700 by the end of 2023, up from approximately 60. Fifteen percent of them specialize in oncology-hematology (APN-OH). Data on their activities, access to continuing education, and expectations are limited.

View Article and Find Full Text PDF

Background: The prognostic impact of TP53 mutations in advanced or metastatic nonsquamous non-small-cell lung cancer (nsNSCLC) patients treated with chemotherapy and/or immune checkpoint inhibitors (ICI) remains unclear.

Materials And Methods: We retrospectively collected data from patients with nsNSCLC treated in the first line from January 2018 to May 2021. The patient was separated into 2 groups according to their TP53 mutation status (wt vs.

View Article and Find Full Text PDF

Background: First-line chemotherapy plus immunotherapy (CT-IO) has recently demonstrated survival benefits over CT alone in extensive-stage small-cell lung cancer (ES-SCLC), based on randomized phase III studies. This retrospective multicenter study assessed the real-world use and effectiveness of CT-IO in ES-SCLC patients.

Patients And Methods: All newly diagnosed ES-SCLC patients from 4 French hospitals treated with CT alone or CT-IO between May 2020 and December 2021 were included.

View Article and Find Full Text PDF
Article Synopsis
  • Canakinumab, a monoclonal antibody targeting IL-1β, was tested in a phase III study (CANOPY-1) to see if it could improve survival rates in patients with advanced non-small-cell lung cancer (NSCLC) when combined with pembrolizumab and chemotherapy.
  • The study involved 643 patients split between canakinumab and placebo groups, with results showing no significant difference in progression-free survival (PFS) or overall survival (OS) after a median follow-up of 21.2 months.
  • While safety profiles were similar, canakinumab treatment led to delays in worsening symptoms like chest pain, coughing, and shortness of breath, suggesting it might
View Article and Find Full Text PDF

Gastric adenocarcinoma (GC) and gastroesophageal junction adenocarcinoma represent frequent and severe diseases whose management has radically changed over the last 10 years. With the advent of second- and third-line standard therapies for metastatic GC patients in the 2010s, the molecular dismemberment of the disease and positive trials with immunotherapy and targeted agents will mark the 2020s. New treatment options have emerged in the neoadjuvant, adjuvant, and metastatic setting.

View Article and Find Full Text PDF
Article Synopsis
  • Early relapse in stage III colon cancer patients, particularly those with proficient mismatch repair (pMMR) and RAS or BRAF mutations, is linked to poorer survival rates after recurrence.
  • * Patients with deficient mismatch repair (dMMR) had fewer recurrences but a shorter median time to recurrence compared to pMMR patients, highlighting the role of molecular status in recurrence patterns.
  • * The study suggests that early relapse significantly impacts survival, especially for those with specific genetic mutations, underlining the importance of molecular profiling in treatment strategies for colon cancer patients.
View Article and Find Full Text PDF

Background: Although brain metastases (BM) at diagnosis are common in non-squamous NSCLC patients (ns-NSCLC), they have been mostly excluded from randomized trials. The aim of this retrospective study was to evaluate real-word outcomes of frontline immune checkpoint inhibitor (ICI) in these patients.

Methods: Our study assess the intracranial and overall efficacy of first-line ICI-based therapy compared to chemotherapy (CT) in ns-NSCLC patients diagnosed with BM, showing no targetable alterations.

View Article and Find Full Text PDF
Article Synopsis
  • The MEDITREME trial tested the safety and efficacy of a combination treatment of durvalumab, tremelimumab, and mFOLFOX6 chemotherapy in patients with RAS-mutant unresectable metastatic colorectal cancer (CRC).
  • The study found no safety issues and met its primary efficacy goal with a 90.7% progression-free survival (PFS) rate at three months for patients with microsatellite stable tumors.
  • Overall, responders showed higher tumor mutational burden and better outcomes linked to immune activity, indicating that this treatment combination is promising for managing MSS mCRC.
View Article and Find Full Text PDF

Purpose: The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against mutations. A phase II study of afatinib in mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).

Patients And Methods: In this phase III study, eligible patients with stage IIIB/IV lung adenocarcinoma were screened for mutations.

View Article and Find Full Text PDF

Background: Prognostic factors of metastatic rectal cancer are not well known.

Aim: The objective of this study was to identify prognostic factors of overall survival (OS) in a cohort of patients with non-resectable synchronous metastatic rectal cancer.

Methods: Patients were retrospectively enrolled from 18 French centres.

View Article and Find Full Text PDF

Background: In CheckMate 9LA (NCT03215706), first-line nivolumab plus ipilimumab with chemotherapy (2 cycles) significantly improved overall survival versus chemotherapy (4 cycles) in patients with metastatic non-small cell lung cancer and no known sensitising epidermal growth factor receptor/anaplastic lymphoma kinase alterations. We present exploratory patient-reported outcomes (PROs; minimum follow-up, 2 years).

Methods: In patients (N = 719) randomised 1:1 to nivolumab plus ipilimumab with chemotherapy or chemotherapy alone, disease-related symptom burden and health-related quality of life were assessed using the Lung Cancer Symptom Scale (LCSS) and 3-level EQ-5D (EQ-5D-3L).

View Article and Find Full Text PDF

Background: To examine the relationship between carcinoembryonic antigen (CEA) kinetics and prognosis in metastatic colorectal cancer (mCRC) patients receiving first-line chemotherapy in the PRODIGE9 trial.

Methods: Associations between monthly CEA measurements within 6 months since baseline and progression-free survival (PFS) were evaluated using a joint-latent class-mixed model. A validation set was used to test our prognosis model.

View Article and Find Full Text PDF

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common adverse effects of antineoplastic agents, ranging in prevalence from 19% to over 85%. Clinically, CIPN is a predominantly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. The high prevalence of CIPN among cancer patients makes it a major problem for both patients and survivors, as well as for their health care providers, especially because there is currently no single effective method of preventing CIPN; moreover, the options for treating this syndrome are very limited.

View Article and Find Full Text PDF

Background: Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor () pathway genes on the efficacy of bevacizumab in metastatic colorectal cancer (mCRC), but results are still inconsistent. The PRODIGE 9 phase III study compared bevacizumab maintenance observation alone after induction chemotherapy with FOLFIRI plus bevacizumab.

Objective: We evaluated the impact of SNPs of , VEGF receptors (), and hypoxia inducible factor-1α () on tumor control duration (TCD), overall survival (OS), progression-free survival (PFS), and duration of first chemotherapy free-intervals (CFI).

View Article and Find Full Text PDF

Cancer is a major public health problem that affects every country in the world. Some countries, most often developed, have made significant diagnostic and therapeutic advances over the years, transforming cancer into a long-term chronic disease and sometimes permitting a cure, even at the metastatic stage. Other countries are lagging behind and the challenge posed by cancer remains as relevant as ever.

View Article and Find Full Text PDF
Article Synopsis
  • The article studies how safe different ways of using a medicine called regorafenib are for patients with a serious bowel cancer that isn't getting better with standard treatments.
  • It looked at three groups of patients who received different doses and schedules of regorafenib, and checked for side effects while they were being treated.
  • The results showed that all dosing methods were generally safe, and one specific schedule seemed to have fewer serious side effects during the first few cycles of treatment.
View Article and Find Full Text PDF

In recent years, advances in molecular diagnostics have transformed the management of advanced non-small-cell lung cancer (NSCLC), allowing for increasingly personalized approaches [...

View Article and Find Full Text PDF